BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q3 2024 Earnings Conference Call November 14, 2024 8:00 AM ET
Company Participants
Vimal Mehta - Chief Executive Officer
Richard Steinhart - Chief Financial Officer
Vincent O'Neill - Executive Vice President, Chief of Product Development and Medical Officer
Rob Risinger - Chief Medical Officer, Neuroscience
Conference Call Participants
Matt Wiley - Senior Vice President and Chief Commercial Officer
Frank Yocca - Chief Scientific Officer
Operator
Good morning, and welcome to the BioXcel Therapeutics Third Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. [Operator Instructions] After the formal remarks, there will be a question-and-answer session. [Operator Instructions]
Just to remind everyone, certain matters discussed in today's conference call and/or answers that may be given to questions asked are forward-looking statements that are subject to risks and uncertainties related to future events and/or the future financial or business performance of the company. Actual results could differ materially from those anticipated in these forward-looking statements.
Risk factors that could affect future results are detailed in the company's quarterly report on Form 10-Q for the quarterly period ended June 30, 2024, which can be found at www.bioxceltherapeutics.com or on www.sec.gov and which will be updated in its quarterly report on Form 10-Q for the quarterly period ended September 30, 2024.
As a reminder, today's call is being recorded. Speaking on today's call are Dr. Vimal Mehta, Chief Executive Officer; and Richard Steinhart, Chief Financial Officer. They will be joining the Q&A session by Dr. Vince O’Neill, Chief of Product Development and Medical Officer; Dr. Frank Yocca, Chief Scientific Officer; and Dr. Rob Risinger, Chief Medical Officer of Neuroscience.
It is now my pleasure to turn the call over to Dr. Mehta. Please go ahead.
Vimal Mehta
Thank you, operator. Good morning, everyone, and thank you for joining us. This past Tuesday, we announced important milestones with our two pivotal Phase 3 trials with BXCL501. These trials are for agitation associated with bipolar disorder or schizophrenia in the home setting and for agitation associated with Alzheimer's dementia. We believe BXCL501 could potentially be a much needed acute treatment option for the millions of patients, who do not have FDA approved therapy for these challenging conditions. Our goal is to transform the treatment paradigm.
Starting with our SERENITY at home trial to evaluate BXCL501 for acute treatment of bipolar or schizophrenia-related agitation, we believe this indication represents a near-term growth opportunity and is our immediate focus area. We designed this study leveraging our substantial clinical experience with BXCL501 conducting 10 double-blinded placebo control trials. We are particularly excited to advance this trial, because it marks the first evaluation of BXCL501 in the home setting.